Colorado Prescription Drug Affordability Review Board & Advisory Council
Colorado’s Prescription Drug Affordability Board (PDAB), established under Senate Bill 21-175, is a Type-1 Board within the Division of Insurance that will have the authority to review prescription drug costs and evaluate their impact on Coloradans. The Board may then recommend ways to address those costs and may set an upper payment limit for certain drugs. The Board has appointed a multi-stakeholder Advisory Council to provide input to the Board to ensure its work is informed by a variety of stakeholders.
- Learning Series
During the Prescription Drug Affordability Board (PDAB) meeting on March 11, Board members identified a number of topic areas where additional learnings and conversations could be helpful to inform the Board's upcoming planned rulemaking activities. As a result, DOI staff have coordinated a five-part “learning series” consisting of optional, virtual webinars to provide education and more information. Learning series will be recorded and posted on the PDAB website. Stakeholders are encouraged to attend these meetings.
Data Deep Dive: May 5 from 11:00 am - 12:15 pm
Join us as we discuss data considerations the PDAB will need to conduct its duties. Presenters include the Program on Regulation, Therapeutics, and Law (PORTAL) from Harvard and Brigham Women’s Hospital, the Center for Improving Value in Health Care (CIVHC), and the Colorado Health Institute (CHI).
Patient Perspectives: May 11 from 12:00 - 1:30 pm
Presenters from the Colorado Consumer Health Initiative (CCHI) and the Chronic Care Collaborative (CCC) will discuss equity implications and share patients’ concerns with prescription drug affordability and access. Researchers from the Skaggs School of Pharmacy at the University of Colorado will present methods to measure patient preference.
Pharmaceutical Supply Chain Panel: May 19 from 9:00 am - 12:00 pm
During the upcoming Prescription Drug Affordability Advisory Council (PDAAC) meeting, a portion of the agenda will be focused on presentations from certain Council members, who will speak to their role and perspective as representatives of drug manufacturers, carriers, wholesalers, PBMs, and providers.
Comparative Effectiveness & Affordability: May 26 from 12:00 - 1:00 pm
Experts from PORTAL and the Skaggs School of Pharmacy will take a deep dive into the relationship between cost effectiveness and affordability.
Register for Comparative Effectiveness & AffordabilityRegister with Closed Captioning
PDAB in Other States: June 3 from 10:00 am - 1:00 pm
During the upcoming Prescription Drug Affordability Board meeting, a portion of the agenda will be dedicated to hearing from other states regarding how their prescription drug affordability laws are similar to and could inform the PDAB’s work. Anticipated states that will present include Maryland and Oregon.
Register for PDAB in Other States/PDAB Meeting
- PDAB Meetings
The Prescription Drug Affordability Board, in accordance with statute, will hold regular meetings every six weeks. All meetings are open to the public except portions of the meeting in which confidential information may be discussed. Board meetings will now be held on the Zoom platform. There will be opportunity for public comment at Board meetings.
- 2022 PDAB Meeting Calendar
- Next PDAB meeting: Friday, June 3 from 10am - 1pm MT
- PDAAC Meetings
The Prescription Drug Affordability Advisory Council (PDAAC), in accordance with statute, will hold meetings quarterly. Advisory Council meetings will now be held on the Zoom platform. There will be opportunity for public comment at PDAAC meetings.
- 2022 PDAAC Meeting Calendar
- Next PDAAC meeting: Thursday, May 19: 9am - 12pm
- Sign up for Division Notifications
To receive PDAB and PDAAC updates directly in your inbox, click the button below. To subscribe, you will need to enter your email and then choose Updates From Divisions > Division of Insurance > Division of Insurance Prescription Drug Affordability Board.
- Contact Information & Accessibility
Questions about the Prescription Drug Affordability Board and Advisory Council can be sent to email@example.com.
The Prescription Drug Affordability Program is committed to providing equal access to our meetings for all participants. If you would like to request an accommodation to attend a Board or Advisory Council meeting, please contact us at firstname.lastname@example.org with your request by the close of business at least one week in advance of a meeting.
- Stakeholder Engagement
Prescription Drug Affordability Board
The Board consists of 5 members with expertise or experience in clinical medicine or health care economics.
Under §10-16-1403, C.R.S, the Board has the following duties:
- Collect and evaluate data on prescription drug costs to identify drugs that may be subject to an affordability review.
- Perform affordability reviews if certain statutory triggers occur. The Board then determines whether a prescription drug is unaffordable for Colorado consumers by analyzing multiple factors set forth in statute.
- If a drug is found to be unaffordable, the Board may set an upper payment limit.
- Make policy recommendations to the General Assembly.
- Board Members
The Governor appointed the following Prescription Drug Affordability Board Members on September 27, 2021:
- Sami Diab, MD of Greenwood Village, Colorado
- Amarylis “Amy” Gutierrez, PharmD of Aurora, Colorado
- Catherine Harshbarger of Holyoke, Colorado
- Gail Mizner, MD, FACP, AAHIVS of Snowmass Village, Colorado and to serve as Board Chair
- James Justin VandenBerg, PharmD, BCPS of Denver, Colorado
- Adopted Policies & Rules
- PDAB Meeting Materials
Prescription Drug Affordability Advisory Council
The Board has appointed a 15 member Advisory Council to provide stakeholder input to the Board on prescription drug affordability. To the extent possible, the Board appointed members who have experience serving underserved communities and who reflect the state’s diversity in terms of race, immigration status, income, disability, age, gender identity, and geography.
- Statutory Requirements
Council members must have knowledge of at least one of the following subject matters:
- The pharmaceutical business model
- Supply chain business models
- The practice of medicine or clinical training
- Health care consumer or patient perspectives
- Healthcare cost trends and drivers
- Clinical and health services research
- The state's health care marketplace
One council member is to be the Executive Director of HCPF or their designee. The Board has appointed the remaining 14 members meeting the following requirements:
- 1 must be on eastern plains
- 1 must be on western slope
- Attempt to appoint members from each congressional district
Conflicts of Interest
- Applicants shall disclose any possible conflict of interest.
- The Board may consider such conflicts in deciding to appoint an applicant to the Council.
- The Chair of the Council must report to the Board any conflicts of interest of the Council and these must be disclosed publicly.
- Council Members
- Kim Bimestefer, Executive Director of HCPF
- Sabrina Walker representing health care consumers
- Gail deVore representing health care consumers
- Edward A. Dauer, LL.B., M.P.H. representing statewide health care advocacy organizations
- Kimberley Jackson, DO representing consumers with chronic diseases and PDAAC Chair
- Maria Fenwick representing a labor union
- Nathan Wilkes representing employers
- Chad Friday representing carriers
- Marc Reece representing pharmacy benefit managers
- Thomas Tobin, MD, MBA representing health care professionals with prescribing authority
- R. Brett McQueen, PhD representing an organization that researches prescription drugs
- Katelin Lucariello MPH representing manufacturers of brand name drugs
- Neal Miller representing manufacturers of generic drugs
- Andrew Gonzales, PharmD representing pharmacists
- Jason Atlas, RPh, MBA representing wholesalers
- PDAAC Meeting Materials
- Conflict of Interest Information
Information required to be disclosed pursuant to §10-16-1402(3)(d) will be contained here.